Expert Interview
Future Trends in Obesity Management: Perceptions of Oral GLP-1s Orforglipron & Danuglipron
Ticker(s): PFE, LLYInstitution: Harvard Medical School
- Medical Director, Obesity Clinic Program and Inpatient Diabetes Program & Associate Professor, Harvard Medical School.
- Manages ~1,000 patients with diabetes.
- Co-Investigator of two landmark studies: the national Diabetes Prevention Program and the Look AHEAD (Action for Health in Diabetes) Study.
- Research interests include diabetes and obesity, metabolic syndrome and obesity and cardiovascular disease with a focus on understanding metabolic and cardiovascular benefits of lifestyle changes and weight loss.
What is your opinion on the potential efficacy and safety of these two therapies (Orforglipron & Danuglipron)?
Added By: pharmaadvisorDo you have an opinion on the potential drug-drug interaction (DDI) profile of the two oral GLP-1s?
Added By: pharmaadvisorGiven the rapidly shifting landscape, what are KOLs' opinions on using these two therapies, and how could they be used in future treatment pathways?
Added By: pharmaadvisorAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
